Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):210–214. doi: 10.1038/bjc.1998.466

Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer.

R A Crawford 1, C Caldwell 1, R K Iles 1, D Lowe 1, J H Shepherd 1, T Chard 1
PMCID: PMC2062899  PMID: 9683295

Abstract

bcl-2 is one of a family of genes that control the apoptotic threshold of a cell. bcl-2 protein and its anti-apoptotic homologue, mcl-1, with the pro-apoptotic protein, bax, are thought to function by forming homo- and heterotypic dimers that then control the progression to apoptosis. p53 is also involved as a down-regulator of bcl-2 and a promoter of bax. To determine the effect of these apoptotic mechanisms, we used immunohistochemistry to determine the prognostic significance of the expression of bcl-2, mcl-1, bax and p53 in primary and recurrent cervical cancer. Tissues from 46 patients with primary cervical cancer and 28 women with recurrent carcinoma were stained for bcl-2, mcl-1, bax and p53. Kaplan-Meier survival analysis was performed using the log-rank test for differences between groups. In the primary disease group, positive staining for bcl-2 was associated with a better 5-year survival (bcl-2 +ve, 84% vs bcl-2 -ve, 53%, P = 0.03). Positive staining for p53 was associated with a survival disadvantage (p53 +ve, 4-year survival 38% vs p53 -ve, 4-year survival 78%, P = 0.02). mcl-1 and bax staining were not useful as prognostic indicators in primary disease. No marker was prognostic in recurrent disease. Positive bcl-2 staining defines a group of patients with primary disease with a good prognosis. p53, an activator of the bax promoter, identifies a group with a worse outcome. In recurrent disease, none of the markers reflected prognosis.

Full text

PDF
210

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994 Apr 15;54(8):2095–2097. [PubMed] [Google Scholar]
  2. Henriksen R., Wilander E., Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer. 1995 Nov;72(5):1324–1329. doi: 10.1038/bjc.1995.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hockenbery D., Nuñez G., Milliman C., Schreiber R. D., Korsmeyer S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22;348(6299):334–336. doi: 10.1038/348334a0. [DOI] [PubMed] [Google Scholar]
  4. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  5. Hunt C. R., Hale R. J., Buckley C. H., Hunt J. p53 expression in carcinoma of the cervix. J Clin Pathol. 1996 Dec;49(12):971–974. doi: 10.1136/jcp.49.12.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kernohan N. M., Cox L. S. Regulation of apoptosis by Bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol. 1996 May;179(1):1–3. doi: 10.1002/(SICI)1096-9896(199605)179:1<1::AID-PATH509>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  7. Krajewski S., Bodrug S., Gascoyne R., Berean K., Krajewska M., Reed J. C. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol. 1994 Sep;145(3):515–525. [PMC free article] [PubMed] [Google Scholar]
  8. Krajewski S., Bodrug S., Krajewska M., Shabaik A., Gascoyne R., Berean K., Reed J. C. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995 Jun;146(6):1309–1319. [PMC free article] [PubMed] [Google Scholar]
  9. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799–1805. [PubMed] [Google Scholar]
  10. Nguyen P. L., Zukerberg L. R., Benedict W. F., Harris N. L. Immunohistochemical detection of p53, bcl-2, and retinoblastoma proteins in follicular lymphoma. Am J Clin Pathol. 1996 May;105(5):538–543. doi: 10.1093/ajcp/105.5.538. [DOI] [PubMed] [Google Scholar]
  11. Norton A. J., Jordan S., Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994 Aug;173(4):371–379. doi: 10.1002/path.1711730413. [DOI] [PubMed] [Google Scholar]
  12. Oltvai Z. N., Korsmeyer S. J. Checkpoints of dueling dimers foil death wishes. Cell. 1994 Oct 21;79(2):189–192. doi: 10.1016/0092-8674(94)90188-0. [DOI] [PubMed] [Google Scholar]
  13. Saegusa M., Takano Y., Hashimura M., Shoji Y., Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer. 1995 Dec 1;76(11):2297–2303. doi: 10.1002/1097-0142(19951201)76:11<2297::aid-cncr2820761118>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  14. Tjalma W., De Cuyper E., Weyler J., Van Marck E., De Pooter C., Albertyn G., van Dam P. Expression of bcl-2 in invasive and in situ carcinoma of the uterine cervix. Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113–117. doi: 10.1016/s0002-9378(98)70636-2. [DOI] [PubMed] [Google Scholar]
  15. Tjalma W., Weyler J., Goovaerts G., De Pooter C., Van Marck E., van Dam P. Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix. J Clin Pathol. 1997 Jan;50(1):33–36. doi: 10.1136/jcp.50.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Uehara T., Kuwashima Y., Izumo T., Kishi K., Shiromizu K., Matsuzawa M. Expression of the proto-oncogene bcl-2 in uterine cervical squamous cell carcinoma: its relationship to clinical outcome. Eur J Gynaecol Oncol. 1995;16(6):453–460. [PubMed] [Google Scholar]
  17. Vaux D. L., Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2239–2244. doi: 10.1073/pnas.93.6.2239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Walboomers J. M., Meijer C. J. Do HPV-negative cervical carcinomas exist? J Pathol. 1997 Mar;181(3):253–254. doi: 10.1002/(SICI)1096-9896(199703)181:3<253::AID-PATH755>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  19. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]
  20. Yang E., Korsmeyer S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996 Jul 15;88(2):386–401. [PubMed] [Google Scholar]
  21. Yang E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995 Jan 27;80(2):285–291. doi: 10.1016/0092-8674(95)90411-5. [DOI] [PubMed] [Google Scholar]
  22. van Diest P. J., van Dam P., Henzen-Logmans S. C., Berns E., van der Burg M. E., Green J., Vergote I. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997 Oct;50(10):801–804. doi: 10.1136/jcp.50.10.801. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES